GlobeNewswire Inc.··NaSepterna's SEP-631 Shows Promise in Mast Cell Disease Treatment
Septerna reports positive Phase 1 data for SEP-631, an experimental oral treatment for mast cell-driven diseases, with plans for Phase 2b development beginning late 2026.
SEPNchronic spontaneous urticariaoral small-molecule